Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. / Buschow, Sonja I; Ramazzotti, Matteo; Reinieren-Beeren, Inge M J; Heinzerling, Lucie M; Westdorp, Harm; Stefanini, Irene; Beltrame, Luca; Hato, Stanleyson V; Ellebaek, Eva; Gross, Stefanie; Nguyen, Van Anh; Weinlich, Georg; Ragoussis, Jiannis; Baban, Dilair; Schuler-Thurner, Beatrice; Svane, Inge M; Romani, Nikolaus; Austyn, Jonathan M; De Vries, I Jolanda M; Schuler, Gerold; Cavalieri, Duccio; Figdor, Carl G.

In: OncoTarget, Vol. 8, No. 40, 2017, p. 67439-67456.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Buschow, SI, Ramazzotti, M, Reinieren-Beeren, IMJ, Heinzerling, LM, Westdorp, H, Stefanini, I, Beltrame, L, Hato, SV, Ellebaek, E, Gross, S, Nguyen, VA, Weinlich, G, Ragoussis, J, Baban, D, Schuler-Thurner, B, Svane, IM, Romani, N, Austyn, JM, De Vries, IJM, Schuler, G, Cavalieri, D & Figdor, CG 2017, 'Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein', OncoTarget, vol. 8, no. 40, pp. 67439-67456. https://doi.org/10.18632/oncotarget.18698

APA

Buschow, S. I., Ramazzotti, M., Reinieren-Beeren, I. M. J., Heinzerling, L. M., Westdorp, H., Stefanini, I., Beltrame, L., Hato, S. V., Ellebaek, E., Gross, S., Nguyen, V. A., Weinlich, G., Ragoussis, J., Baban, D., Schuler-Thurner, B., Svane, I. M., Romani, N., Austyn, J. M., De Vries, I. J. M., ... Figdor, C. G. (2017). Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. OncoTarget, 8(40), 67439-67456. https://doi.org/10.18632/oncotarget.18698

Vancouver

Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I et al. Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. OncoTarget. 2017;8(40):67439-67456. https://doi.org/10.18632/oncotarget.18698

Author

Buschow, Sonja I ; Ramazzotti, Matteo ; Reinieren-Beeren, Inge M J ; Heinzerling, Lucie M ; Westdorp, Harm ; Stefanini, Irene ; Beltrame, Luca ; Hato, Stanleyson V ; Ellebaek, Eva ; Gross, Stefanie ; Nguyen, Van Anh ; Weinlich, Georg ; Ragoussis, Jiannis ; Baban, Dilair ; Schuler-Thurner, Beatrice ; Svane, Inge M ; Romani, Nikolaus ; Austyn, Jonathan M ; De Vries, I Jolanda M ; Schuler, Gerold ; Cavalieri, Duccio ; Figdor, Carl G. / Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. In: OncoTarget. 2017 ; Vol. 8, No. 40. pp. 67439-67456.

Bibtex

@article{1fd4ea02c57148e59ac9b7ee3dcb0810,
title = "Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein",
abstract = "Immunotherapy for metastatic melanoma offers great promise but, to date, only a subset of patients have responded. There is an urgent need to identify ways of allocating patients to the most beneficial therapy, to increase survival and decrease therapy-associated morbidity and costs. Blood-based biomarkers are of particular interest because of their straightforward implementation in routine clinical care. We sought to identify markers for dendritic cell (DC) vaccine-based immunotherapy against metastatic melanoma through gene expression analysis of peripheral blood mononuclear cells. A large-scale microarray analysis of 74 samples from two treatment centers, taken directly after the first round of DC vaccination, was performed. We found that phosphatidylethanolamine binding protein 1 (PEBP1)/Raf Kinase inhibitory protein (RKIP) expression can be used to identify a significant proportion of patients who performed poorly after DC vaccination. This result was validated by q-PCR analysis on blood samples from a second cohort of 95 patients treated with DC vaccination in four different centers. We conclude that low PEBP1 expression correlates with poor overall survival after DC vaccination. Intriguingly, this was only the case for expression of PEBP1 after, but not prior to, DC vaccination. Moreover, the change in PEBP1 expression upon vaccination correlated well with survival. Further analyses revealed that PEBP1 expression positively correlated with genes involved in T cell responses but inversely correlated with genes associated with myeloid cells and aberrant inflammation including STAT3, NOTCH1, and MAPK1. Concordantly, PEBP1 inversely correlated with the myeloid/lymphoid-ratio and was suppressed in patients suffering from chronic inflammatory disease.",
keywords = "Journal Article",
author = "Buschow, {Sonja I} and Matteo Ramazzotti and Reinieren-Beeren, {Inge M J} and Heinzerling, {Lucie M} and Harm Westdorp and Irene Stefanini and Luca Beltrame and Hato, {Stanleyson V} and Eva Ellebaek and Stefanie Gross and Nguyen, {Van Anh} and Georg Weinlich and Jiannis Ragoussis and Dilair Baban and Beatrice Schuler-Thurner and Svane, {Inge M} and Nikolaus Romani and Austyn, {Jonathan M} and {De Vries}, {I Jolanda M} and Gerold Schuler and Duccio Cavalieri and Figdor, {Carl G}",
year = "2017",
doi = "10.18632/oncotarget.18698",
language = "English",
volume = "8",
pages = "67439--67456",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "40",

}

RIS

TY - JOUR

T1 - Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein

AU - Buschow, Sonja I

AU - Ramazzotti, Matteo

AU - Reinieren-Beeren, Inge M J

AU - Heinzerling, Lucie M

AU - Westdorp, Harm

AU - Stefanini, Irene

AU - Beltrame, Luca

AU - Hato, Stanleyson V

AU - Ellebaek, Eva

AU - Gross, Stefanie

AU - Nguyen, Van Anh

AU - Weinlich, Georg

AU - Ragoussis, Jiannis

AU - Baban, Dilair

AU - Schuler-Thurner, Beatrice

AU - Svane, Inge M

AU - Romani, Nikolaus

AU - Austyn, Jonathan M

AU - De Vries, I Jolanda M

AU - Schuler, Gerold

AU - Cavalieri, Duccio

AU - Figdor, Carl G

PY - 2017

Y1 - 2017

N2 - Immunotherapy for metastatic melanoma offers great promise but, to date, only a subset of patients have responded. There is an urgent need to identify ways of allocating patients to the most beneficial therapy, to increase survival and decrease therapy-associated morbidity and costs. Blood-based biomarkers are of particular interest because of their straightforward implementation in routine clinical care. We sought to identify markers for dendritic cell (DC) vaccine-based immunotherapy against metastatic melanoma through gene expression analysis of peripheral blood mononuclear cells. A large-scale microarray analysis of 74 samples from two treatment centers, taken directly after the first round of DC vaccination, was performed. We found that phosphatidylethanolamine binding protein 1 (PEBP1)/Raf Kinase inhibitory protein (RKIP) expression can be used to identify a significant proportion of patients who performed poorly after DC vaccination. This result was validated by q-PCR analysis on blood samples from a second cohort of 95 patients treated with DC vaccination in four different centers. We conclude that low PEBP1 expression correlates with poor overall survival after DC vaccination. Intriguingly, this was only the case for expression of PEBP1 after, but not prior to, DC vaccination. Moreover, the change in PEBP1 expression upon vaccination correlated well with survival. Further analyses revealed that PEBP1 expression positively correlated with genes involved in T cell responses but inversely correlated with genes associated with myeloid cells and aberrant inflammation including STAT3, NOTCH1, and MAPK1. Concordantly, PEBP1 inversely correlated with the myeloid/lymphoid-ratio and was suppressed in patients suffering from chronic inflammatory disease.

AB - Immunotherapy for metastatic melanoma offers great promise but, to date, only a subset of patients have responded. There is an urgent need to identify ways of allocating patients to the most beneficial therapy, to increase survival and decrease therapy-associated morbidity and costs. Blood-based biomarkers are of particular interest because of their straightforward implementation in routine clinical care. We sought to identify markers for dendritic cell (DC) vaccine-based immunotherapy against metastatic melanoma through gene expression analysis of peripheral blood mononuclear cells. A large-scale microarray analysis of 74 samples from two treatment centers, taken directly after the first round of DC vaccination, was performed. We found that phosphatidylethanolamine binding protein 1 (PEBP1)/Raf Kinase inhibitory protein (RKIP) expression can be used to identify a significant proportion of patients who performed poorly after DC vaccination. This result was validated by q-PCR analysis on blood samples from a second cohort of 95 patients treated with DC vaccination in four different centers. We conclude that low PEBP1 expression correlates with poor overall survival after DC vaccination. Intriguingly, this was only the case for expression of PEBP1 after, but not prior to, DC vaccination. Moreover, the change in PEBP1 expression upon vaccination correlated well with survival. Further analyses revealed that PEBP1 expression positively correlated with genes involved in T cell responses but inversely correlated with genes associated with myeloid cells and aberrant inflammation including STAT3, NOTCH1, and MAPK1. Concordantly, PEBP1 inversely correlated with the myeloid/lymphoid-ratio and was suppressed in patients suffering from chronic inflammatory disease.

KW - Journal Article

U2 - 10.18632/oncotarget.18698

DO - 10.18632/oncotarget.18698

M3 - Journal article

C2 - 28978044

VL - 8

SP - 67439

EP - 67456

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 40

ER -

ID: 185993317